Search for: "Par Pharmaceutical"
Results 61 - 80
of 303
Sorted by Relevance
|
Sort by Date
24 Apr 2011, 9:30 pm
By James DeGiulio -- Pozen Secures Injunction Blocking Par's Generic Treximet Earlier this month, Pozen obtained a preliminary injunction blocking Par Pharmaceutical from marketing a generic version of Pozen's migraine drug Treximet until an infringement suit over the drug is resolved. [read post]
23 Sep 2010, 9:20 pm
By James DeGiulio -- Sham Litigation Claims against Par and Paddock Continue in AndroGel Litigation Par Pharmaceutical and Paddock Laboratories received clarification that their agreements with Solvay not to release competing versions of the testosterone supplement AndroGel are still subject to sham litigation claims brought by direct purchasers. [read post]
20 Aug 2013, 7:57 am
Andrews recently denied defendant Par Pharmaceutical's motion to preclude the testimony of Plaintiff's expert. [read post]
26 Oct 2007, 10:39 am
Par Pharmaceuticals v. [read post]
29 Nov 2015, 9:54 pm
• Defendants: Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC; Par Pharmaceutical, Inc. [read post]
12 May 2010, 5:49 pm
The members of the Creditors' Committee are: Par Pharmaceutical, Inc. [read post]
18 Oct 2008, 8:19 am
In the Hatch-Waxman area, Pozen, Inc. announced Par Pharmaceutical Inc. has filed an application with the Food and Drug Administration [FDA] to make a generic version of Treximet, a migraine treatment Pozen developed with GlaxoSmithKline PLC, and shares of Pozen shed nearly 28 percent of their value on 17 Oct. 08 [read post]
18 Oct 2012, 1:00 am
Par Pharmaceutical Inc., the Federal Circuit upheld the district court’s determination that the patents at issue were not invalid as obvious and were infringed by the subject Abbreviated New Drug Applications (ANDAs). [read post]
10 Oct 2011, 10:00 am
In addition, Par may extend the modafinil supply agreement for another year. [read post]
19 Apr 2009, 7:13 pm
Par Pharmaceutical, Inc. v. [read post]
19 Jul 2012, 8:07 am
As matters stand right now, this is clearly not the case when it comes to patent protection for pharmaceutical inventions. [read post]
14 Jun 2010, 6:12 pm
Par Pharmaceutical filed an ANDA to make a time-released version of the opiate tramadol. [read post]
19 Apr 2012, 8:17 pm
Par Pharmaceutical Inc. 1:12-cv-00419; filed April 4, 2012 in the District Court of Delaware Infringement of U.S Patent Nos. 7,619,004 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued November 17, 2009), 7,601,758 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics in the Treatment of Gout Flares," issued October 13, 2009), 7,820,681 ("Methods for Concomitant Administration of Colchicine… [read post]
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
The complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories. [read post]
20 Oct 2011, 2:30 pm
Par Pharmaceuticals recently challenged (here and here) FDA’s authority in the off-label promotion arena on First Amendment and Administrative Procedure Act grounds. [read post]
18 Jan 2012, 10:33 am
Ill, Filed Jan. 11, 2012 Insurance companies, self-insured employers, and union health and welfare plans filed the class action in Illinois Federal Court alleging several RICO violations against Walgreen Co. and Par Pharmaceutical Co. for engaging in a scheme to overcharge for generic versions of Zantac and Prozac. [read post]
31 Jul 2020, 4:48 am
Complete Business Solutions Group Inc. d/b/a/ Par Funding et al. [read post]
13 May 2007, 5:18 pm
Par Pharmaceuticals Inc. et. al.1:07-cv-00255; filed May 9, 2007 in the District... [read post]
28 Oct 2007, 9:50 pm
Par Pharmaceutical Inc. et al. 1:07-cv-00666; filed October 24, 2007 in the... [read post]
20 May 2015, 1:00 am
Wall Street Journal, Rules Fail To Rein In Tax-Driven Takeovers: Endo International PLC agreed to buy rival drug maker Par Pharmaceutical Holdings Inc. for $8 billion, the latest in a string of cross-border mergers steering tax revenue away from the U.S., despite Washington’s efforts. [read post]
